Pliant Therapeutics (PLRX) Projected to Announce Quarterly Earnings on Thursday

Pliant Therapeutics (NASDAQ:PLRX) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.33) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Pliant Therapeutics (NASDAQ:PLRX) last announced its earnings results on Monday, May 11th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.04. On average, analysts expect Pliant Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pliant Therapeutics Price Performance

Shares of PLRX stock opened at $1.05 on Thursday. Pliant Therapeutics has a 1-year low of $1.05 and a 1-year high of $1.95. The company has a market cap of $65.02 million, a price-to-earnings ratio of -0.57 and a beta of 1.21. The stock has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.22.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PLRX shares. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $3.00.

Hedge Funds Weigh In On Pliant Therapeutics

Hedge funds have recently made changes to their positions in the company. Jump Financial LLC purchased a new position in shares of Pliant Therapeutics in the second quarter valued at approximately $30,000. Canada Pension Plan Investment Board acquired a new stake in shares of Pliant Therapeutics in the second quarter worth approximately $36,000. Engineers Gate Manager LP increased its position in shares of Pliant Therapeutics by 139.4% during the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock worth $36,000 after purchasing an additional 18,300 shares in the last quarter. HRT Financial LP purchased a new stake in shares of Pliant Therapeutics during the fourth quarter worth approximately $39,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Pliant Therapeutics during the fourth quarter worth approximately $47,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).